← Back

Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of critical care products. Its FDA-approved product LYMPHIR is a targeted immunotherapy for cutaneous T-cell lymphoma. The late-stage pipeline includes Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation for anti-inflammatory and anesthetic relief in hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for ARDS. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Country

USA

Sector

Pharmaceuticals

Themes

Oncology Therapeutics

Also in

Immuno-Oncology / Checkpoint

Price · split & dividend adjusted

News & notes moving CTXR

CTXR▼

Citius Pharmaceuticals misses Q3 estimates with wider loss and lower revenue

Citius Pharmaceuticals reported fiscal third quarter 2026 results that fell short of expectations. GAAP EPS came in at a loss of $0.34, missing by $0.09, while revenue of $1.5 million missed by $8.27 million. The company had cash and cash equivalents of $17.0 million as of June 30, 2026.

CTXR ▼

Seeking Alpha·32dRead more →